A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma.
about
Optimal duration of androgen deprivation therapy following radiation therapy in intermediate- or high-risk nonmetastatic prostate cancer: A systematic review and metaanalysisA comprehensive review of contemporary role of local treatment of the primary tumor and/or the metastases in metastatic prostate cancerRationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancerProstate Stem Cell Antigen Expression in Radical Prostatectomy Specimens Predicts Early Biochemical Recurrence in Patients with High Risk Prostate Cancer Receiving Neoadjuvant Hormonal TherapySalvage focal prostate cryoablation for locally recurrent prostate cancer after radiotherapy: initial results from the cryo on-line data registry.The long-term outcomes of radical prostatectomy for very high-risk prostate cancer pT3b-T4 N0-1 on definitive histopathology.Current status of radical prostatectomy for high-risk prostate cancer.Neoadjuvant hormone therapy following treatment with robotic-assisted radical prostatectomy achieved favorable in high-risk prostate cancer.Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancerNeo-adjuvant hormone therapy for non-metastatic prostate cancer: a systematic review and meta-analysis of 5,194 patients.Management of high-risk localized prostate cancer.Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localThe relation between age and androgen deprivation therapy use among men in the Medicare population receiving radiation therapy for prostate cancerAdditional therapy for high-risk prostate cancer treated with surgery: what is the evidence?Novel treatment methods for localized prostate cancer: hypofractionated robotic radiation therapy and adjuvant chemotherapy.Emerging drugs for prostate cancer.Neoadjuvant therapy preceding prostatectomy for prostate cancer: rationale and current trials.Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence.Radical prostatectomy as primary treatment of high-risk prostate cancer.Androgen deprivation therapy: past, present and future.Molecular markers to guide primary radical treatment selection in localized prostate cancer.Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancerNeoadjuvant Treatment of High-Risk, Clinically Localized Prostate Cancer Prior to Radical Prostatectomy.Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation.SEOM clinical guidelines for treatment of prostate cancer.Complications and functional results of surgery for locally advanced prostate cancer.Evaluation of vesicular stomatitis virus mutant as an oncolytic agent against prostate cancer.Radical Prostatectomy as a First-Line Treatment in Patients with Initial PSA >20 ng/mL.Significance of neoadjuvant hormonal therapy in radical retropubic prostatectomy: a retrospective single-surgeon study.[11C]Choline PET/CT in therapy response assessment of a neoadjuvant therapy in locally advanced and high risk prostate cancer before radical prostatectomyThe Effects of Enzalutamide Monotherapy on Multiparametric 3T MR Imaging in Prostate Cancer.Immunohistochemical expression of PDGFR, VEGF-C, and proteins of the mToR pathway before and after androgen deprivation therapy in prostate carcinoma: significant decrease after treatment.Long-term oncological outcome in men with T3 prostate cancer: radical prostatectomy versus external-beam radiation therapy at a single institution.Curative radiation therapy in prostate cancer.Influence of androgen deprivation therapy on choline PET/CT in recurrent prostate cancer.Cryosurgery for clinical T3 prostate cancer.Prognostic factors in Chinese patients with prostate cancer receiving primary androgen deprivation therapy: validation of Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score and impacts of pre-existing obesity and diabetes mellitus.Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade.Radical prostatectomy versus high-dose irradiation in localized/locally advanced prostate cancer: A Swedish multicenter randomized trial with patient-reported outcomes.Management of Biochemical Recurrence after Primary Curative Treatment for Prostate Cancer: A Review.
P2860
Q26801000-A1E31A23-1F9E-4135-9900-9AEF8AAEE86BQ27000180-416F3AF3-C1C5-467D-A722-8F21754E2142Q27028084-16D6DF29-1F0F-4316-83E1-A58AE0B0D196Q28550782-27603B47-308D-44E7-990A-1FF8FAB19E02Q30857429-11FE9883-64A3-4845-B86C-1E831B163D75Q33609747-A52597CF-B1E7-4095-B1AB-79FC8BB5F556Q34346841-70FA83E9-F02F-46A4-B16A-24EA81F5EFCFQ34758084-59E02566-CBBB-4BA7-8FC5-7D0AB6E63CCFQ35079955-FE1A9E02-74BA-4E01-A842-6A72C6430646Q35132144-00AF254D-D5BD-440D-8460-D18D2AD43F39Q35503645-35183397-2E27-4B4B-9D54-7B020E0180A9Q35704002-4B2CA302-34A6-48FB-AD51-28070F6AE153Q36665817-BF975409-18D6-47CB-8EA9-1F9C910B902CQ37546041-8BE651F0-927E-4AC8-8109-6B73C3DB4071Q37546045-34F1496A-2148-4BFB-B834-18DAB6634CE1Q37570555-3567A204-0FC7-4E27-B1A7-BA0F0F6A112DQ37705424-77045532-98A4-408F-B874-24A1773D2D1BQ37735433-64DF3151-14A7-499C-B677-0573FCC0AF44Q37982319-635DEE12-AF72-4C28-A342-97C814839EC0Q38016530-44494C99-611E-4B13-9C4C-01E615D51D0AQ38226242-7E7332B4-7076-4CD3-93E1-26085F4FF919Q38599748-AB2B7652-F312-4AED-8E4F-F05A31B7B4F9Q38770371-8470B3F3-B034-4214-B50C-C4224514753EQ38830640-C05657FF-9458-47C2-B715-BEA1D56BC6E8Q40043274-01E1C87C-6699-416E-9CA3-1178F49FA1AEQ40625979-8CF0822D-2FD5-407E-B506-02463B520883Q41379521-615B236E-C0ED-4F4C-A5B6-2DDBC0C5C84EQ42103015-32DA2C31-568A-4741-B282-D40697714859Q42169535-2D63046D-5FD7-40BE-97E0-B903D8CFD71DQ42319922-DB150F33-5DE1-4EB9-8ABE-BEB97F4D6BF5Q42704331-64E04360-7EA1-474C-B50D-E77C784FE2C7Q43867243-FC2BBEF0-3327-4E6C-A8B6-257BDE85012CQ44294983-4A20C4CE-E7F9-4622-9AD8-08283F2A721DQ44666799-FDE28D45-B842-49A0-8665-4B14894AB537Q45384878-B58C7533-5FD8-4B26-8F7C-535879115854Q46087183-87C3F9EE-6271-40EE-9A82-75D1C7FCC1CDQ47178893-4546916E-4BF5-4C3A-87DD-142F518EBC66Q47273306-7C961317-AC6D-413B-A7E7-10518FEAEF6DQ47793289-574CBD6C-200D-439D-BA6C-6A39F7B7E0B1Q47826406-7AE4356B-F097-40C9-9220-E033E5CB70A8
P2860
A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma.
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
A systematic review and meta-a ...... y advanced prostate carcinoma.
@ast
A systematic review and meta-a ...... y advanced prostate carcinoma.
@en
type
label
A systematic review and meta-a ...... y advanced prostate carcinoma.
@ast
A systematic review and meta-a ...... y advanced prostate carcinoma.
@en
prefLabel
A systematic review and meta-a ...... y advanced prostate carcinoma.
@ast
A systematic review and meta-a ...... y advanced prostate carcinoma.
@en
P2093
P1476
A systematic review and meta-a ...... y advanced prostate carcinoma.
@en
P2093
P356
10.1016/J.CTRV.2008.08.002
P577
2008-10-15T00:00:00Z